Quantcast

IMAC Holdings Reports 2018 Financial Results; Significant Revenue Growth Reflects Addition of Five Clinics During the Year

By GlobeNewswire,  April 17, 2019, 08:30:00 AM EDT


BRENTWOOD, Tenn., April 17, 2019 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq:IMAC), a provider of Innovative Medical Advancements and Care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces financial results for the 12 months ended December 31, 2018. Financial results for 2018 reflect the acquisitions of IMAC Regeneration Center of Kentucky, IMAC Regeneration Center of St. Louis, and Advantage Therapy beginning in June, bringing the total number of IMAC locations to 11, compared with two locations in 2017.

Highlights of 2018 include the following (all financial comparisons are with IMAC Holdings, Inc. for 2017, unless otherwise indicated):

  • Net revenues were $6.7 million, up 753%
  • Net loss was $3.1 million, compared with $0.1 million
  • Acquired full ownership interest in the Ozzie Smith IMAC Regeneration Centers in Chesterfield and St. Peters, Missouri in June 2018
  • Took over management of the IMAC Regeneration Center in Paducah and Murray, Kentucky in July 2018
  • Launched the Tony Delk IMAC Regeneration Center in Lexington, Kentucky in July 2018
  • Acquired full ownership of four Advantage Therapy clinics in Springfield, Missouri in August 2018
  • Acquired a majority interest in BioFirma, LLC to support the Company's proprietary regenerative medicine developments
  • Pro forma 2018 net revenues, which refer to the IMAC Group predecessor company, were $10.5 million, compared with pro forma net revenues for 2017 of $9.5 million, an increase of 9.3%

Additional highlights since the close of 2018 include:

  • Engaged legendary NFL Coach Mike Ditka as brand ambassador for the Company's expansion into Chicago, and entered into a definitive agreement to acquire three clinics in the Chicago suburbs
  • Completed an underwritten initial public offering (IPO) of common stock and warrants, raising gross proceeds of $4.3 million

Management Commentary

"We are proud of our many significant accomplishments during 2018, which was an exceptionally active year as we acquired full ownership and/or took over management of eight clinics in three geographies. In parallel, we prepared for and completed our IPO with plans to utilize the proceeds to fund further expansion," said Jeff Ervin, IMAC's chief executive officer. "Given our rapid growth and numerous new centers, it is difficult to compare year-over-year financial results. Yet when viewed against prior-year facility revenue, we are pleased with the growth in pro forma net patient revenues of 9.3%. In addition, as previously announced, we believe growth in pro forma patient visits and procedures during the fourth quarter of 21.8% and 23.0%, respectively, bodes well for our success in 2019 and beyond."

"Looking forward to 2019, our immediate priority is to close on the announced acquisition of the Chicago clinics which we expect this week. We are pleased that the transaction generated several inquiries from similar clinics which we believe will lead us to opportunities for favorable partnerships," Mr. Ervin concluded.

2018 Financial Results

Net revenues for 2018 were $6.7 million, compared with $0.8 million in 2017, a gain of 753%. Patient service revenues increased to $6.6 million, from $0.7 million during 2017.

Cost of revenues were $0.9 million in 2018 compared to $0.1 million in 2017, with the increase in costs primarily attributable to the Company's 2018 acquisitions and an increase in supply costs associated with a full year of service for IMAC of Tennessee.

Salaries and benefit expense were $4.7 million and $1.0 million in 2018 and 2017, respectively. The increase is attributable to acquisitions, a full year of staff expense at IMAC of Tennessee and the costs related to the preparation of the Company's IPO. Acquisition salaries and benefit expense was $2.5 million in 2018, with no acquisition-related salaries and benefit expense in 2017. Advertising and marketing expense was $0.9 million and $0.1 million in 2018 and 2017, respectively. Advertising for acquisitions was $0.3 million and $0 in 2018 and 2017, respectively. General and administrative expense was $3.1 million and $0.5 million in 2018 and 2017, respectively, with $1.1 million of this increase due to acquisitions.

Depreciation and amortization expense was $0.7 million and $0.1 million in 2018 and 2017, respectively. The increase was due to amortization costs associated with the acquisitions of IMAC of Kentucky, IMAC Regeneration Center of St. Louis, and Advantage Therapy, and a full year of depreciation expense related to IMAC of Tennessee and the assets of the acquired companies.

Earnings Gain (Loss) before equity of non-consolidated affiliates was ($3.7) million and ($0.9) million in 2018 and 2017, respectively. Acquisitions accounted for $0.1 million of the increase while the loss for new facilities decreased by $0.3 million in 2018, compared with 2017.

The Company had cash and cash equivalents of $0.2 million as of December 31, 2018. Forty-five days after the end of the year, the Company raised $4.3 million in gross proceeds from its Initial Public Offering.

Pro forma Information

IMAC Group represents IMAC Holdings, Inc. on a pro forma basis after consummation of business transactions involving companies owning or managing IMAC Regeneration Centers and the related issuance of shares of common stock, debt and/or cash payments in such transactions, which were completed between June and August 2018. The business transactions refer to the following five transactions with entities for which IMAC Holdings had either no ownership or control, or varying degrees of ownership or control: Integrated Medicine and Chiropractic Regeneration Center PSC, IMAC Regeneration Center of St. Louis, LLC, Advantage Hand Therapy and Orthopedic Rehabilitation, LLC, and BioFirma LLC. A fifth acquisition relates to the buyout of the minority ownership of other parties of IMAC Regeneration Management of Nashville, LLC.

The table below contains select consolidated financial and other data that has been derived from unaudited consolidated financial statements for 2018 and 2017. The timing of acquisitions completed during the years presented affects the comparability of the selected financial data. The following table covers periods both prior to and subsequent to the transactions. The following selected consolidated financial and other data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and the related notes included elsewhere in this report. The results presented below are not necessarily indicative of future results:

    Year Ended December 31,  
    2018     2017  
    (unaudited)  
Procedures     291,571       258,300  
growth %     12.88 %        
Visits     111,939       96,326  
growth %     16.21 %        
                 
Statements of Operations Data:                
Gross revenue   $ 27,455,352     $ 25,812,212  
Contractual adjustments     (16,964,446 )     (16,215,897 )
Net revenues     10,490,906       9,596,315  
Other revenue     -       -  
Total revenue   $ 10,490,906     $ 9,596,315  
                 
Net (loss) attributable to IMAC Holdings, Inc.   $ (3,747,007 )   $ (1,328,513 )

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. It owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening two Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, and a Tony Delk IMAC Regeneration Center. IMAC's outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids.

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as "anticipate," "expect," "believe," "may," "will," "should" or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers' requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

More information about IMAC Holdings, Inc. is available at www.imacregeneration.com

IMAC Press Contact:

Laura Fristoe 

lfristoe@imacrc.com

Investors

LHA Investor Relations

Kim Sutton Golodetz

(212) 838-3777

kgolodetz@lhai.com

(Tables to follow)

# # #



IMAC Holdings, Inc.

Consolidated Balance Sheets

December 31, 2018 and 2017



    December 31,  
    2018     2017  
ASSETS            
Current assets:                
Cash   $ 194,316     $ 127,788  
Accounts receivable, net     303,630       138,981  
Due from related parties     -       347,648  
Other assets     170,169       94,045  
Total current assets     668,115       708,463  
                 
Property and equipment, net     3,333,638       542,791  
                 
Other assets:                
Goodwill     2,042,125       -  
Intangible assets, net     4,257,434       -  
Deferred IPO Costs     335,318       -  
Security deposits     438,163       27,828  
Total other assets     7,073,040       27,828  
                 
Total assets   $ 11,074,793     $ 1,279,082  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                
                 
Current liabilities:                
Accounts payable and accrued expenses   $ 1,261,582     $ 56,665  
Acquisition liabilities     7,259,208       -  
Patient deposits     454,380       130,906  
Due to related parties     -       95,501  
Notes payable, current portion     4,459,302       157,932  
Capital lease obligation, current portion     16,740       7,820  
Line of credit     379,961       25,000  
Total current liabilities     13,831,173       473,824  
                 
Long-term liabilities:                
Notes payable, net of current portion     317,291       456,152  
Capital Lease Obligation, net of current portion     84,038       52,494  
Deferred Rent     197,991       64,753  
Lease Incentive Obligation     576,454       60,428  
                 
Total liabilities     15,006,947       1,107,651  
                 
Committments and contingencies                
                 
Stockholders' equity (deficit):                
Preferred stock - $0.001 par value, 5,000,000 authorized, nil issued and outstanding                
Common stock; $0.001 par value, 30,000,000 authorized, 6,582,737 shares issued and outstanding     6,583       6,583  
                 
Additional paid-in capital     1,231,917       1,231,917  
Accumulated deficit     (3,544,820 )     (491,076 )
Non-controlling interest     (1,625,840 )     (575,994 )
Total stockholders' equity (deficit)     (3,932,160 )     171,430  
                 
Total liabilities and stockholders' equity (deficit)   $ 11,074,787     $ 1,279,081  



IMAC Holdings, Inc.

Consolidated Statements of Operations

For the Years Ended

December 31, 2018 and 2017

    2018     2017  
             
Patient revenues   $ 16,135,967     $ 1,378,313  
Contractual adjustments     (9,498,896 )     (723,688 )
Total patient revenue, net     6,637,071       654,625  
                 
Management fees     64,000       131,400  
Total revenue     6,701,071       786,025  
                 
Operating expenses:                
Patient expenses     933,907       63,216  
Salaries and benefits     4,730,035       967,627  
Share-based compensation     14,998       18,747  
Advertising and marketing     859,191       119,867  
General and administrative     3,063,270       465,740  
Depreciation and amortization     651,066       65,895  
Total operating expenses     10,252,467       1,701,092  
                 
Operating loss     (3,551,396 )     (915,067 )
                 
Other income (expense):                
Interest income     7,541       14,821  
Other income (loss)     18,356       (2,744 )
Interest expense     (153,824 )     (27,151 )
Total other income (expenses)     (127,927 )     (15,074 )
                 
Loss before equity in earnings (loss) of non-consolidated affiliate     (3,679,323 )     (930,141 )
                 
Equity in earnings (loss) of non-consolidated affiliate     (105,550 )     13,609  
                 
Net loss before income taxes     (3,784,873 )     (916,532 )
                 
Income taxes     -       -  
                 
Net loss     (3,784,873 )     (916,532 )
                 
Net loss attributable to the noncontrolling interest     731,130       859,351  
                 
Net loss attributable to IMAC Holdings, Inc.   $ (3,053,743 )   $ (57,181 )
                 
Net loss per share attributable to common stockholders                
Basic and diluted   $ (0.46 )   $ (0.01 )
                 
Weighted average common shares outstanding                
Basic and diluted     6,582,737       6,552,679  

Source: IMAC Holdings, Inc.

This article appears in: News Headlines

Referenced Stocks: IMAC










Today's Market Activity

NASDAQ 7997.64
1.56  ▲  0.02%
DJIA 26586.66
137.12  ▲  0.52%
S&P 500 2907.61
7.16  ▲  0.25%
Data as of Apr 18, 2019 | 3:18PM